Clinical Trial Update: Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET) [Phase 3]

View source ↗

Summary

A Phase 3 randomized trial comparing pegylated interferon alfa-2a to hydroxyurea in high-risk polycythemia vera and high-risk essential thrombocythemia has comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Thrombocythemia
• Polycythemia Vera

Drugs mentioned

• HYDROXYUREA (Hydroxyurea)
• Pegylated interferon alfa-2a (Peginterferon alfa-2a)

Snippet

Sponsor: Ronald Hoffman | Conditions: High Risk Polycythemia Vera, High Risk Essential Thrombocythemia | Phase 3 | Status: COMPLETED | Results posted: 2018-07-24